首页> Cancer discovery> Overcoming Genetically Based Resistance Mechanisms to PD-1 Blockade.

Overcoming Genetically Based Resistance Mechanisms to PD-1 Blockade.

导出 OA

翻译打印收藏纠错

第一作者： Davis Y,Torrejon

第一单位： Division of Hematology-Oncology, Department of Medicine, University of California, Los Angeles, Los Angeles, California.

作者： Davis Y,Torrejon ^[1] ; Gabriel,Abril-Rodriguez ^[2] ; Ameya S,Champhekar ^[1] ; Jennifer,Tsoi ^[1] ; Katie M,Campbell ^[1] ; Anusha,Kalbasi ^[3] ; Giulia,Parisi ^[1] ; Jesse M,Zaretsky ^[1] ; Angel,Garcia-Diaz ^[1] ; Cristina,Puig-Saus ^[1] ; Gardenia,Cheung-Lau ^[4] ; Thomas,Wohlwender ^[4] ; Paige,Krystofinski ^[1] ; Agustin,Vega-Crespo ^[1] ; Christopher M,Lee ^[1] ; Pau,Mascaro ^[1] ; Catherine S,Grasso ^[1] ; Beata,Berent-Maoz ^[1] ; Begoña,Comin-Anduix ^[5] ; Siwen,Hu-Lieskovan ^[1] ; Antoni,Ribas ^[6]

作者单位： Division of Hematology-Oncology, Department of Medicine, University of California, Los Angeles, Los Angeles, California. ^[1] Division of Hematology-Oncology, Department of Medicine, University of California, Los Angeles, Los Angeles, California.;Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, California. ^[2] Department of Radiation Oncology, University of California, Los Angeles, Los Angeles, California. ^[3] Division of Surgical Oncology, Department of Surgery, University of California, Los Angeles, Los Angeles, California. ^[4] Division of Surgical Oncology, Department of Surgery, University of California, Los Angeles, Los Angeles, California.;Jonsson Comprehensive Cancer Center, Los Angeles, California. ^[5] Division of Hematology-Oncology, Department of Medicine, University of California, Los Angeles, Los Angeles, California. aribas@mednet.ucla.edu.;Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, California.;Division of Surgical Oncology, Department of Surgery, University of California, Los Angeles, Los Angeles, California.;Jonsson Comprehensive Cancer Center, Los Angeles, California.;Parker Institute for Cancer Immunotherapy, San Francisco, California. ^[6]

医学主题词动物(Animals);CD4阳性T淋巴细胞(CD4-Positive T-Lymphocytes);CD8阳性T淋巴细胞(CD8-Positive T-Lymphocytes);细胞系, 肿瘤(Cell Line, Tumor);细胞增殖(Cell Proliferation);抗药性, 肿瘤(Drug Resistance, Neoplasm);人类(Humans);干扰素类(Interferons);白细胞介素2(Interleukin-2);Janus激酶1(Janus Kinase 1);Janus激酶2(Janus Kinase 2);杀伤细胞, 天然(Killer Cells, Natural);小鼠, 近交C57BL(Mice, Inbred C57BL);肿瘤(Neoplasms);聚乙烯二醇类(Polyethylene Glycols);Toll样受体9(Toll-Like Receptor 9);β2微球蛋白(beta 2-Microglobulin)

DOI 10.1158/2159-8290.CD-19-1409

PMID 32467343

发布时间 2022-10-05

基金项目

T32 CA009120/CA/NCI NIH HHS/United States P01 CA244118/CA/NCI NIH HHS/United States P01 CA168585/CA/NCI NIH HHS/United States T32 GM008042/GM/NIGMS NIH HHS/United States R44 CA250889/CA/NCI NIH HHS/United States R35 CA197633/CA/NCI NIH HHS/United States U54 CA199090/CA/NCI NIH HHS/United States P30 CA016042/CA/NCI NIH HHS/United States P30 AI028697/AI/NIAID NIH HHS/United States

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交